Evidence map›Paper›PMID 32865605›Full record

ArticleCancer immunology, immunotherapy : CII2021

Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE).

Archana Thakur, Sri Vidya Kondadasula, Kyungmin Ji, Dana L Schalk, Edwin Bliemeister, Johnson Ung, Amro Aboukameel, Eli Casarez, Bonnie F Sloane, Lawrence G Lum

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Archana Thakur *Bone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA. at2fx@virginia.edu.ORCID http://orcid.org/0000-0003-3876-9555
Sri Vidya Kondadasula *Departments of Oncology and Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA.
Kyungmin JiDepartment of Pharmacology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA.
Dana L SchalkBone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
Edwin BliemeisterBone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
Johnson UngBone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
Amro AboukameelDepartments of Oncology and Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA.
Eli CasarezBone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
Bonnie F SloaneDepartment of Pharmacology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, 48201, USA.
Lawrence G LumBone Marrow Transplant Program, Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, 1335 Lee Street, West Complex 7191, Charlottesville, VA, 22908, USA.
University of Virginia Cancer CenterWayne State University · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Breast Cancer Treatment with Antibody Targeted T CellsR01CA092344 · NCI · WAYNE STATE UNIVERSITY · PI LUM, LAWRENCE G · 2002 to 2012
$4.6M
Targeting Neuroblastoma with armed T cellsR01CA182526 · NCI · WAYNE STATE UNIVERSITY · PI CHEUNG, NAI-KONG V, LUM, LAWRENCE G · 2014 to 2019
$3.9M
Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015
$2.5M
NCI NIH HHS P30 CA022453NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA 092344NCI NIH HHS R01 CA092344NCI NIH HHS R01 CA 140314NCI NIH HHS R01 CA140314NCI NIH HHS R01 CA 182526NCI NIH HHS R01 CA182526University of Virginia Cancer Center startup funds
6 · The paper itself

Abstract

Adoptive transfer of Bispecific antibody Armed activated T cells (BATs) showed promising anti-tumor activity in clinical trials in solid tumors. The cytotoxic activity of BATs occurs upon engagement with tumor cells via the bispecific antibody (BiAb) bridge, which stimulates BATs to release cytotoxic molecules, cytokines, chemokines, and other signaling molecules extracellularly. We hypothesized that the release of BATs Induced Tumor-Targeting Effectors (TITE) by this complex interaction of T cells, bispecific antibody, and tumor cells may serve as a potent anti-tumor and immune-activating immunotherapeutic approach. In a 3D tumorsphere model, TITE showed potent cytotoxic activity against multiple breast cancer cell lines compared to control conditioned media (CM): Tumor-CM (T-CM), BATs-CM (B-CM), BiAb Armed PBMC-CM (BAP-CM) or PBMC-CM (P-CM). Multiplex cytokine analysis showed high levels of Th

Indexed as

Cytotoxicity, ImmunologicImmunomodulationAnimalsAntibodies, BispecificAntineoplastic Agents, ImmunologicalBiomarkersCell Line, TumorCells, CulturedCytokinesDisease Models, AnimalGene Expression ProfilingHumansImmunophenotypingLymphocyte ActivationMiceNeoplasmsAntibodies, BispecificAntineoplastic Agents, ImmunologicalBiomarkersCytokines3D culture modelActivated T cellsBispecific antibodyBreast cancerCancer stem cellsMyeloid-derived suppressor cellsTh1 cytokines

Identifiers

PMID32865605
PMCPMC7914128
OpenAlexW3081949237

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.